Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors

Immunopharmacology and Immunotoxicology

Volumn 30, Issue 3, 2008, Pages 609-621

  Passantino, Letizia ^a,c   Passantino, Giuseppe ^a   Cianciotta, Attilio ^a   Ribaud, Maria Rosaria ^a   Lo Presti, Giuseppe ^a   Ranieri, Girolamo ^b   Perillo, Antonella ^a  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c Facolta di Medicina Veterinaria   (Italy)

Author keywords

C kit; Cytochemistry; Dog; Mastocytomas; Morphometry

Indexed keywords

STEM CELL FACTOR;

ANIMAL DISEASE; ANIMAL TISSUE; ARTICLE; CELL DENSITY; DOG; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MASTOCYTOMA; MICROVASCULATURE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; PROTO ONCOGENE C KIT; SKIN CANCER;

ANIMALS; DOG DISEASES; DOGS; IMMUNOHISTOCHEMISTRY; MAST CELLS; MASTOCYTOMA, SKIN; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

CANIS FAMILIARIS;

EID: 48349100967     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970801949265     Document Type: Article

References (49)

1. Brodey, R.S. Canine and feline neoplasia. Adv. Vet. Sci. Comp. 1970, 14, 309-354.
2. Finnie, J.W.; Bostock, D.E. Skin neoplasia in dogs. Aust. Vet. J. 1979, 55 (12), 602-604.
3. Priester, W.A. Skin tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J. Natl. Cancer Inst. 1973, 50 (2), 457-466.
4. Rothwell, T.L.; Howlett, C.R.; Middleton, D.J.; Griffiths, D.A.; Duffs, B.C. Skin neoplasm of dogs in Sidney. Aust. Vet. J. 1987, 64 (6), 161-164.
5. Macy D.W. Canine mast cell tumors. Vet. Clin. North. Small Anim. Pract. 1985, 15 (4), 783-803.
6. Bostock, B.E. The prognosis following surgical removal of mastocytomas in dogs. J. Small Anim. Pract. 1973, 14 (1), 27-40.
7. Patnaik, A.K.; Ehler, W.J.; MacEwen, E.G. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet. Pathol. 1984, 21 (5), 469-474.
8. Zemke, D.; Yamini, B.; Yuzbasiyan-Gurkan, V. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the protooncogene c-KIT. J. Vet. Diagn. Invest. 2001, 13 (4), 341-345.
9. Bostock, D.E. The prognosis following surgical removal of mastocytomas in dogs. J. Small Anim. Pract. 1973, 14 (1), 27-41.
10. Hottendorf, G.H.; Nielsen, S.W. Pathologic survey of 300 extirpated canine mastocytomas. Zentralbl. Veterinarmed. [A.] 1967, 14 (3), 272-281.
11. Simoes, J.P.; Schoning, P.; Butine, M. Prognosis of canine mast cell tumors: A comparison of three methods. Vet. Pathol. 1994, 31 (6), 637-647.
12. Abadie, J.J.; Amardeilh, M.A.; Delverdier, M.E. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J. Am. Vet. Med. Assoc. 1999, 215 (11), 1629-1634.
13. Bostock, D.E.; Crocker, J.; Harris, K.; Smith, P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br. J. Cancer, 1989 59 (6), 915-918.
14. Ginn, P.E.; Fox, L.E.; Brower, J.C.; Gaskin, A.M; Kurzman, I.D.; Kubilis, P.S. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet. Pathol. 2000, 37 (1), 33-39.
15. Jaffe, M.H.; Hosgood, G.; Taylor, H.W.; Kerwin, S.C.; Hedlund, C.S.; Lopez, M.K.; Davidson, J.R.; Miller, D.M.; Paranjpe, M. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet. Pathol. 2000, 37 (1), 40-46.
16. Kravis, L.D.; Vail, D.M.; Kisseberth, W.C.; Ogilvie, G.K.; Volk, L.M. Frequency of argyrophilic nucleolar organizer regions in fine-needle aspirates and biopsy specimens from mast cell tumors in dogs. J. Am. Vet. Med. Assoc. 1996, 209 (8), 1418-1420.
17. Ali, S.; Ali, S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).Gene, 2007, 401 (1-2), 38-45.
18. Hornick, J.L.; Fletcher, C.D. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum. Pathol. 2007, 38(5), 679-687.
19. th International Workshop and Conference, 1993 Nov 3-7. Oxford University Press, Oxford, 1995, pp. 1882-8.
20. Columbo, M.; Horowitz, E.M.; Botana, L.M.; MacGlashan, D.W. Jr.; Bochner, B.S.; Gillis, S.; Zsebo, K.M.; Galli, S.J.; Lichtenstein, L.M. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J. Immunol. 1992, 149 (2), 599-608.
21. Yarden, Y.; Kuang, W.J.; Yang-Feng, T.; Coussens, L.; Munemitsu, S.; Dull, T.J.; Chen, E.; Schlessinger, J.; Francke, U.; Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987, 6 (11), 3341-3351.
22. Meininger, C.J.; Yano, H.; Rottapel, R.; Bernstein, A.; Zsebo, K.M.; Zetter, B.R. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood, 1992, 79 (4), 958-963.
23. Dastych, J.; Metcalfe, D.D. Stem cell factor induces mast cell adhesion to fibronectin. J. Immunol. 1994, 152 (1), 213-219.
24. Nocka, K.; Buck, J.; Levi, E.; Besmer, P. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO. J. 1990, 9 (10), 3287-3294.
25. Tsai, M.; Takeishi, T.; Thompson, H.; Langley, K.E.; Zsebo, K.M.; Metcalfe, D.D.; Geissler, E.N.; Galli, S.J. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88 (14), 6382-6386.
26. Yee, N.S.; Paek, I.; Besmer, P. Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: Basis for radiosensitivity of white spotting and steel mutant mice. J. Exp. Med. 1994, 179 (6), 1777-1787.
27. Reguera, M.J.; Ferrer, L.; Rabanal, R.M. Evaluation of an intron deletion in the c-kit gene of canine mast cell tumors. AJVR, 2002, 63 (9), 1257-1261.
28. London, C.A.; Galli, S.J.; Yuuki, T.; Hu, Z.Q.; Helfand, S.C.; Geissler, E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 1999, 27 (4), 689-697.
29. London, C.A.; Kissenberth, W.C.; Galli, S.J.; Geissler, E.N.; Helfand, S.C. Expression of stem cell factor receptor (c-kit) by malignant mast cells from spontaneous canine mast cell tumours. J. Comp. Pathol. 1996, 113, 399-414.
30. Reguera, M.J.; Ranabal, R.M.; Puigdemont, A.; Ferrer, L.; Canine mast cell tumors express stem cell factor receptor. Am. J. Dermapathol. 2000, 22 (1), 49-54.
31. Kiupel M., Webster J.D., Kaneene J.B., Miller R., Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet. Pathol. 2004, 41: 371-377.
32. Polverini, P.J. How the extracellular matrix and macrophages contribute to angiogenesis-dependent disease. Eur. J. Cancer, 1996, 32A (14), 2430-1437.
33. Norrby, K.; Wooley, D. Role of mast cells in mitogenesis and angiogenesis in normal tissues and tumor tissue. Adv. Biosc. 1993, 89, 71-115.
34. Benelli, R.; Morini, M.; Carrozzino, F.; Ferrari, N.; Minghelli, S.; Santi, L.; Cassatela, M.; Noonan, D.M.; Albini, A. Neutrophils as a key cellular target for angiostatin: Implications for regulation of angiogenesis and inflammation. FASEB J 2002, 16 (2), 267-269.
35. Folkman, J. What is the cevidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82 (1), 4-6.
36. Takahashi, Y.; Kitadai, Y.; Bucana, C.D.; Cleary, K.R.; Ellis, L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55 (18), 3964-3968.
37. Bochner, B.H.; Cote, R.J.; Weidner, N.; Groshen, S.; Chen, S.C.; Skinner, D.G.; Nichols, P.W. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst. 1995, 87 (21), 1603-1612.
38. Tanigawa, N.; Amaya, H.; Matsumura, M.; Shimomatsuya, T.; Horiuchi, T.; Muraoka, R.; Iki, M. Extent of tumor vascularization correlates with prognosis and hematougenous metastasis in gastric carcinomas. Cancer Res. 1996, 56 (11), 2671-2676.
39. Gasparini, G. Angiogenesis research up to 1996. A commentary on the state of the art and suggestions for future studies. Eur. J. Cancer, 1996, 32A (14), 2397-2385.
40. Gasparini, G. Clinical significance of determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur. J. Cancer, 1996, 32A (14), 2485-1493.
41. Ferrara, N.; Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161 (2), 851-858.
42. Biglietto, G.; Romano, A.; Maglione, D.; Rambaldi, M.; Paletti, I.; Lago, C.T.; Califano, D.; Monaco, C.; Mineo, A.; Santelli, G.; Manzo, G.; Botti, G.; Chiappetta, G.; Persico, M.G. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene, 1996, 13 (3), 577-587.
43. Takebayshi, Y.; Akiyama, S.; Akiba, S.; Yamada, K.; Miyadera, K.; Sumizawa, T.; Yamada, Y.; Murata, F.; Aikou, T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 1996, 88 (16), 1110-1117.
44. Takahashi, Y.; Bucana, C.D.; Liu, W.; Yoneda, J.; Kitadai, Y.; Cleary, K.R.; Ellis, L.M. Platelet-derived endothelial cell growth factor in human cancer angiogenesis: Role of infiltrating cells. J. Natl. Cancer Inst. 1996, 88 (16), 1146-1151.
45. Mise, M.; Arii, S.; Higashituji, H.; Furutani, M.; Niwano, M.; Harada, T.; Istigami, S.; Toda, Y.; Nakayama, H.; Fukumoto, M.; Fujita, J.; Imamura, M. Clinical significance of vascular endothelial cell growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology, 1996, 23 (3), 455-464.
46. Koukourakis, M.I.; Giatromanolaki, A.; O'Byrne, K.J.; Comley, M.; Whitehouse, R.M.; Talbot, D.C.; Gatter, K.C.; Harris, A.L. Platelet-derived endothelial cell growth factor expression correlates with tumor angiogenesis and prognosis in non-small-cell lung cancer. Br. J. Cancer, 1997, 75 (4), 477-481.
47. Ranieri, G.; Passantino, L.; Patruno, R.; Passantino, G.; Jirillo, F.; Catino, A.; Mattioli, V.; Gadaleta, C.; Ribatti, D. The dog mast cell tumor as a model to study the relationship between angiogenesis, mast cell density and tumor malignancy. Oncol. Rep. 2003, 10 (5), 1189-1193.
48. Marchevsky, A.M. and Erler, B.S. Morphometry in pathology. In: Image Analysis: A Primer for Pathologists, Marchevsky, A.M.; Bartels, P.H., Eds., pp. 125-179. Raven Press, New York, 1994.
49. Furitsu, T.; Tsujimura, T; Tono, T.; Ikeda, H.; Kitayama, H.; Koshimizu, U.; Sugahara, H.; Butterfield, J.H.; Ashman, L.K.; Kanayama, Y.; Matsuzawa, Y.; Kitamura, Y.; Kanakura, Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 1993, 92(4), 1736-1744.